Marileda Novello

Marileda Novello

Auto-generated profile, based on publicly available information

Marileda Novello

Internal Medicine, Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2006 in JAMA
Verified
Journal Article
Open access
PDF file
LSLeonardo A. Sechi
Leonardo A. Sechi
MNMarileda Novello
Marileda Novello
RLRoberta Lapenna
Roberta Lapenna
SBSara Baroselli
Sara Baroselli
ENElisa Nadalini
Elisa Nadalini
CCCristiana Catena
Cristiana Catena
Primary aldosteronism is a form of endocrine hypertension characterized by high blood pressure, hypokalemia, suppressed plasma renin activity, and inappropriate aldosterone secretion. Recent studies have reported a greater frequency of primary aldosteronism among patients with hypertension than the previously accepted prevalence of approximately 1%.1,2 Such increased frequency may be the result of more effective identification of this condition due to widespread use of the aldosterone-renin ratio as a screening test.3 Although primary aldosteronism is considered correctable with either removal of an adrenal adenoma or administration of mineralocorticoid receptor antagonists, in many cases, hypertension may persist after treatment.4

1 September 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CCCristiana Catena
Cristiana Catena
RLRoberta Lapenna
Roberta Lapenna
SBSara Baroselli
Sara Baroselli
ENElisa Nadalini
Elisa Nadalini
GianLuca ColussiGianLuca Colussi
GianLuca Colussi
LSLeonardo A. Sechi
Leonardo A. Sechi
Context: The relationship between aldosterone and glucose metabolism is poorly understood, and there is substantial disparity among findings of studies that have examined glucose tolerance and insulin sensitivity in patients with primary aldosteronism. Objective: The objective of the study was to determine the outcome of glucose tolerance and insulin sensitivity in patients with primary aldosteronism after treatment. Design: This was a prospective study of patients who received a diagnosis of primary aldosteronism and were followed up for an average period of 5.7 yr (range, 3–9 yr). Setting: The study was conducted at a university referral center. Patients: A consecutive sample of 47 patients with tumoral or idiopathic aldosteronism was followed up after either surgical or medical treatment. Patients with primary aldosteronism were compared with 247 patients with essential hypertension with the same severity and duration of disease and 102 normotensive subjects. Main Outcome Measures: Short- and long-term changes in glucose tolerance and insulin sensitivity were measured. Results: After adjustment for age, gender, and body mass index, patients with primary aldosteronism had greater homeostasis model assessment index (P < 0.05) and plasma insulin response to an oral glucose load (P < 0.05) and lower quantitative insulin sensitivity check index (P < 0.01) than normotensive controls. Changes in insulin sensitivity were significantly greater in essential hypertension than primary aldosteronism, and this difference was confirmed by assessment with the hyperinsulinemic-euglycemic clamp (P < 0.01). Treatment of primary aldosteronism decreased blood pressure significantly, and during the initial 6 months of follow-up, parameters of insulin sensitivity were restored to normal. Analysis of subsequent follow-up showed nonsignificant changes in glucose metabolism parameters in both adrenalectomized and spironolactone-treated patients. Conclusions: Insulin resistance is present in patients with tumoral and idiopathic aldosteronism, but the defect appears less severe than in patients with essential hypertension. Treatment with surgery or aldosterone antagonists restores rapidly and persistently normal sensitivity to insulin.

1 November 2003 in American Journal of Hypertension
Verified
Journal Article
Closed access
CCCristiana Catena
Cristiana Catena
GGGilberta Giacchetti
Gilberta Giacchetti
MNMarileda Novello
Marileda Novello
GianLuca ColussiGianLuca Colussi
GianLuca Colussi
ACAlessandro Cavarape
Alessandro Cavarape
LSLeonardo A Sechi
Leonardo A Sechi
Feeding a high-fructose diet induces hypertension and insulin-resistance in Sprague-Dawley rats. To investigate whether insulin receptors contribute to abnormal glucose metabolism and whether their regulation is differentially regulated in different tissues, we evaluated the glycemic and insulinemic response to an oral glucose load, insulin receptor binding, and insulin receptor messengerRNA (mRNA) levels in tissues of rats that were fed either standard rat chow or a diet containing 66% fructose for 2 weeks. Blood pressure and plasma triglycerides increased significantly in the fructose-fed rats, whereas body weight, fasting plasma glucose, and plasma insulin did not differ significantly from controls. Plasma glucose and insulin responses to oral glucose were significantly greater in fructose-fed than in control rats. Insulin receptor-binding characteristics were determined by an in situ autoradiographic technique associated with computerized microdensitometry. The insulin receptor number was significantly lower in both skeletal muscle and liver of fructose-fed rats as compared to controls, whereas no difference was observed in the kidney. No significant differences were found in binding affinity. Insulin receptor mRNA levels were determined by slot-blot hybridization with a cRNA probe encoding the 5' end of the rat insulin receptor cDNA. Consistent with binding data, mRNA levels were significantly lower in skeletal muscle and liver of fructose-fed rats as compared to controls, but not in the kidney. Decreased number of insulin receptors occurring at the level of gene expression is present in skeletal muscle and liver of fructose-fed rats and might contribute to insulin resistance in this model.

1 December 2003 in Kidney International
Verified
Journal Article
Closed access
CCCristiana Catena
Cristiana Catena
ACAlessandro Cavarape
Alessandro Cavarape
MNMarileda Novello
Marileda Novello
GGGilberta Giacchetti
Gilberta Giacchetti
LSLeonardo A. Sechi
Leonardo A. Sechi

1 December 2008 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
LSLeonardo A. Sechi
Leonardo A. Sechi
MNMarileda Novello
Marileda Novello
GianLuca ColussiGianLuca Colussi
GianLuca Colussi
AFAlessandro Di Fabio
Alessandro Di Fabio
ACAlessandra Chiuch
Alessandra Chiuch
CCCristiana Catena
Cristiana Catena
Background. Components of the renin–angiotensin–aldosterone system (RAAS) and a prothrombotic state are predictors of cardiovascular events in hyperten

1 September 2005 in Journal Of Hypertension
Verified
Journal Article
Closed access
CCCristiana Catena
Cristiana Catena
MNMarileda Novello
Marileda Novello
RLRoberta Lapenna
Roberta Lapenna
SBSara Baroselli
Sara Baroselli
GianLuca ColussiGianLuca Colussi
GianLuca Colussi
LSLeonardo A Sechi
Leonardo A Sechi
Although adequate control of blood pressure is of basic importance in cardiovascular prevention in hypertensive patients, correction of additional risk factors is an integral part of their management. In addition to classical risk factors, epidemiological research has identified a number of other conditions that might significantly contribute to cardiovascular risk in the general population and might achieve specific relevance in patients with high blood pressure. In fact, more than 20% of patients with premature cardiovascular events do not have any of the traditional risk factors and, although effective intervention on blood pressure and additional risk factors has significantly reduced cardiovascular morbidity and mortality, the contribution to stroke, coronary artery disease and renal failure is still unacceptably high. Evaluation of new risk factors may further expand our capacity to predict atherothrombotic events when these factors are included along with the traditional ones in the assessment of global cardiovascular risk in hypertensive patients. Because it could be anticipated that the role of these novel factors will become increasingly evident in the future, researchers with an interest in hypertension and physicians dealing with problems related to cardiovascular prevention should give them appropriate consideration. This review summarizes the basic biology and clinical evidence of two emerging risk factors that are reciprocally related and contribute to the development and progression of organ damage in hypertension: the prothrombotic state and lipoprotein(a).